485 related articles for article (PubMed ID: 18093051)
1. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform.
Liao KH; Tan YM; Conolly RB; Borghoff SJ; Gargas ML; Andersen ME; Clewell HJ
Risk Anal; 2007 Dec; 27(6):1535-51. PubMed ID: 18093051
[TBL] [Abstract][Full Text] [Related]
2. Chloroform mode of action: implications for cancer risk assessment.
Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
[TBL] [Abstract][Full Text] [Related]
3. Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation.
Tan YM; Butterworth BE; Gargas ML; Conolly RB
Toxicol Sci; 2003 Sep; 75(1):192-200. PubMed ID: 12805651
[TBL] [Abstract][Full Text] [Related]
4. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
[TBL] [Abstract][Full Text] [Related]
5. Development of a quantitative model incorporating key events in a hepatotoxic mode of action to predict tumor incidence.
Luke NS; Sams R; DeVito MJ; Conolly RB; El-Masri HA
Toxicol Sci; 2010 May; 115(1):253-66. PubMed ID: 20106946
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of chloroform by cytochrome P450 2E1 is required for induction of toxicity in the liver, kidney, and nose of male mice.
Constan AA; Sprankle CS; Peters JM; Kedderis GL; Everitt JI; Wong BA; Gonzalez FL; Butterworth BE
Toxicol Appl Pharmacol; 1999 Oct; 160(2):120-6. PubMed ID: 10527910
[TBL] [Abstract][Full Text] [Related]
7. Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations.
David RM; Clewell HJ; Gentry PR; Covington TR; Morgott DA; Marino DJ
Regul Toxicol Pharmacol; 2006 Jun; 45(1):55-65. PubMed ID: 16439044
[TBL] [Abstract][Full Text] [Related]
8. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene.
Covington TR; Robinan Gentry P; Van Landingham CB; Andersen ME; Kester JE; Clewell HJ
Regul Toxicol Pharmacol; 2007 Feb; 47(1):1-18. PubMed ID: 16901594
[TBL] [Abstract][Full Text] [Related]
9. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points.
Bogen KT; Gold LS
Regul Toxicol Pharmacol; 1997 Feb; 25(1):26-42. PubMed ID: 9056499
[TBL] [Abstract][Full Text] [Related]
10. Chloroform: exposure estimation, hazard characterization, and exposure-response analysis.
Meek ME; Beauchamp R; Long G; Moir D; Turner L; Walker M
J Toxicol Environ Health B Crit Rev; 2002; 5(3):283-334. PubMed ID: 12162870
[TBL] [Abstract][Full Text] [Related]
11. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
Kirman CR; Sweeney LM; Corley R; Gargas ML
Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
[TBL] [Abstract][Full Text] [Related]
12. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride.
Delic JI; Lilly PD; MacDonald AJ; Loizou GD
Regul Toxicol Pharmacol; 2000 Oct; 32(2):144-55. PubMed ID: 11067771
[TBL] [Abstract][Full Text] [Related]
13. Bayesian analysis of a physiologically based pharmacokinetic model for perchloroethylene in humans.
Qiu J; Chien YC; Bruckner JV; Fisher JW
J Toxicol Environ Health A; 2010; 73(1):74-91. PubMed ID: 19953421
[TBL] [Abstract][Full Text] [Related]
14. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
15. Chloroform-induced cytolethality in freshly isolated male B6C3F1 mouse and F-344 rat hepatocytes.
Ammann P; Laethem CL; Kedderis GL
Toxicol Appl Pharmacol; 1998 Apr; 149(2):217-25. PubMed ID: 9571991
[TBL] [Abstract][Full Text] [Related]
16. Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition.
Nong A; Tan YM; Krolski ME; Wang J; Lunchick C; Conolly RB; Clewell HJ
J Toxicol Environ Health A; 2008; 71(20):1363-81. PubMed ID: 18704829
[TBL] [Abstract][Full Text] [Related]
17. Physiologically-based pharmacokinetic modeling of benzene in humans: a Bayesian approach.
Yokley K; Tran HT; Pekari K; Rappaport S; Riihimaki V; Rothman N; Waidyanatha S; Schlosser PM
Risk Anal; 2006 Aug; 26(4):925-43. PubMed ID: 16948686
[TBL] [Abstract][Full Text] [Related]
18. Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age.
Allen BC; Hack CE; Clewell HJ
Risk Anal; 2007 Aug; 27(4):947-59. PubMed ID: 17958503
[TBL] [Abstract][Full Text] [Related]
19. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
[TBL] [Abstract][Full Text] [Related]
20. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.
Kitchin KT; Conolly R
Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
